Nuo Therapeutics, Inc. (AURX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67059V2097
Nuo Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.31 m USD |
| Gross profit | 2.22 m USD |
| Operating income | -2.52 m USD |
| EBIT | -2.51 m USD |
| Net income | -2.51 m USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
More stocks
- KAANAPALI LAND LLC (KANP)
- Daesung Hi-Tech Co. Ltd. (129920.KQ)
- Dongbang Trans (004140.KS)
- Solid Year Co., Ltd. (6737.TWO)
- Kinetic Group Inc (KNIT)
- Changs Ascending Enterprise Co., Ltd. (8038.TWO)
- Toivo Group Oyj (TOIVO.HE)
- Chi Sheng Chemical (4111.TWO)
- Envoy Medical, Inc. (COCH)
- Ecoplastic Corporation (038110.KQ)
- Greenland Mines Ltd (GRML)
- SurplusGLOBAL, Inc. (140070.KQ)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.